USPTO serial 90027055
Serial No. 90027055
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BEVERLY, JOSETTE MICHELLE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 90027055?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Darren B. Cohen
Darren B. Cohen REED SMITH LLP599 LEXINGTON AVENUENEW YORK, NY 10022UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business advisory, development, and strategic planning services provided to companies for business purposes in the life sciences industries; Business consultation services in the field of GxP (Good Practice) compliance; Business consulting services on processes and workflows related to content creation, localization and publishing strategy including Translation Memory and Terminology Management, Quality Management, Life Sciences Regulatory Compliance and Risk Management; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Regulatory submission management, namely, assisting others in preparing and filing applications for new medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology with governmental regulatory bodies around the world; Regulatory submission management, namely, providing simultaneous multiple country submissions of applications for the registration and approval of medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology; providing information online regarding regulatory submission management; Business management consulting, strategic planning and business advisory services provided to medical, medical technology, biopharmaceutical, and biotechnology companies, and government agencies, educational and research institutions, law firms, and investment firms in the fields of biologics, pharmaceuticals and medical devices; Providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for drug and medical device approval; Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs and medical devices with governmental regulatory bodies; Business consulting services in the field of biologics, pharmaceuticals, prescription drugs and medical devices; Business consulting and management for companies in the life sciences fields pertaining to business operations including standard operating procedures, audits and assessments; Business consulting and for companies in the life sciences fields related to supply chain management, including, internet of medical things (IoMT), connected service and quality management, product lifecycle management, product master management, and enterprise resource planning; Providing quality and IT staffing services for companies in the life sciences fields and employment consultation pertaining to staffing augmentation services and onsite and remote on-demand compliance staff augmentation; Business consulting and management for companies in the life sciences fields pertaining to business operations including information and data compiling and analyzing relating to business management; consulting services in the field of medical device product approval for commercial purposes; Business consulting and management for companies in the life sciences fields for use in the following applications: validation and qualification; including, computer software assurance, manufacturing system validation, laboratory equipment and instrumentation, process validation and cleaning validation, laboratory information management systems (LIMS), facilities and utilities, and manufacturing systems; Business consulting and management for companies in the life sciences fields for use in the following applications: compliance strategy: including laboratory validation, assessments, strategy and remediation planning, performing remediation activities, and providing advisory services to assist GxP labs in meeting commercial and regulatory requirements; Business consulting and management for companies in the life sciences fields for use in the following applications: digital transformation strategy, including: support on demand services, development on demand services; Business consulting and management for companies in the life sciences fields for use in the following applications: management; including life sciences and program management, GxP cloud services, and organizational change management | ACTIVE | — |
| 041 | Providing educational programs in the life science fields using on-line activities, non-downloadable webinars and blogs, workshops, and printable materials distributed therewith featuring Regulatory issues and developments, GxP (Good Practice) Compliance, Risk Management, Design Control, QMS (Quality Management Solutions), CSV (Computer System Validation), SOP (Standard Operating Procedures), Data Integrity, UDI (Unique Device Identification), Regulatory readiness, and other related practice areas in the life sciences fields | ACTIVE | — |
| 042 | Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; biotechnology research consulting services; pharmaceutical research and product development for use in manufacturing; information technology consultation services; computer aided design services; Consulting services for others in the field of designing pre-clinical and clinical studies and trials for others; product research and development for others in the fields of biologics, pharmaceuticals, prescription drugs and medical devices; quality management services, namely, quality evaluation and analysis, quality assurance and quality control in the field of biologics, pharmaceuticals, prescription drugs and medical devices; scientific consulting and research services relating to the field of pharmaceuticals, medical devices, and life sciences, namely, biology, and medicine; design and development and technical verification consulting services in the fields of biotechnology and pharmaceutical research, and scientific and technological services, namely, scientific research, analysis, testing, and related scientific studies in the field of chemistry and molecular biology, namely, biologics and protein detection, characterization, analysis and testing; Computer consulting services in the field of cloud computing in the field of life science; Technical and scientific research consulting and computer project management for companies in the life sciences fields pertaining to cloud-based data migration; Technical and scientific consulting and management for companies in the life sciences fields pertaining to technical verification and validation laboratory equipment and instrumentation; Technical and scientific consulting and management for companies in the life sciences fields pertaining to digital compression of computer data; Technical and scientific consulting and management for companies in the life sciences fields pertaining to GxP (Good Practice) cloud seeding services; Technical and scientific consulting and management for companies in the life sciences fields for use in the following applications: regulation support; including standard operating procedures, customized compliance training programs, clinical compliance as service (CaaS), medical device cybersecurity, medical device compliance, data integrity, serialization/track and trace, global unique device identification, good clinical practice (GCP) compliance and quality assurance, risk-based monitoring, auditing as a service (AaaS), risk management, remediation planning and execution, emerging companies compliance roadmapping, EU MDR and IVDR compliance, and audits and assessments; Technical and management for companies in the life sciences fields for use in the following applications: supply chain management; including, internet of medical things (IoMT), connected service and quality management, product lifecycle management, product master data management, and enterprise resource planning; Technical and scientific consulting and management for companies in the life sciences fields for use in the following applications: compliance strategy: including laboratory validation, assessments, strategy and remediation planning, performing remediation activities, and providing advisory services to assist GxP labs in meeting commercial and regulatory requirements; Technical and scientific consulting and management for companies in the life sciences fields for use in the following applications: management; including life sciences and program management, GxP cloud services, and organizational change management (OCM) | ACTIVE | — |
| 045 | Regulatory compliance consulting services in the life sciences fields, namely, reviewing standards and practices to assist clients with compliance with governmental laws, regulations and rules pertaining to medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology; providing technical regulatory affair consulting services directed to medical, medical technology, biopharmaceutical, and biotechnology companies in order to assure compliance with food and drug administration's laws and regulations; provision of information online pertaining to regulatory compliance in the fields of medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology; and regulatory compliance consulting in the fields of biologics, pharmaceuticals, prescription drugs and medical devices | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by US Data Management, LLC
- Other trademarks owned by US Data Management, LLC
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 045
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 28, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 28, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 20, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 18, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 18, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 18, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 23, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 29, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 29, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 9, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 20, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 28, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 15, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 30, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 28, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 27, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 2, 2020 | NWAP | NEW APPLICATION ENTERED | — |